EP3654951A1 — Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv
Assigned to Janssen Sciences Ireland ULC · Expires 2020-05-27 · 6y expired
What this patent protects
The present invention provides methods of treating HIV-infected individuals once daily with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and the like. , and a prodrug of tenofovir, or a salt of it.
USPTO Abstract
The present invention provides methods of treating HIV-infected individuals once daily with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and the like. , and a prodrug of tenofovir, or a salt of it.
Drugs covered by this patent
- Tybost (COBICISTAT) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.